Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?

References

• Pritchard A. Statistical bibliography or bibliometrics. J Doc. 1969; 25:348–349.
   Web of Science ®Google Scholar
• Antoniou SA, Lasithiotakis K, Koch OO, et al. Bibliometric analysis of scientific contributions in minimally invasive general surgery. Surg Laparosc Endosc Percutan Tech. 2014; 24:26–30.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu G, Long X, et al. A bibliometric analysis of classic publications in web of science category of orthopedics. J Orthop Surg Res. 2019;14:227.
   PubMed Web of Science ®Google Scholar
• O’Sullivan KE, Kelly JC, Hurley JP. The 100 most cited publications in cardiac surgery: a bibliometric analysis. Ir J Med Sci. 2015;184:91–99.
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Falagas ME. A bibliometric analysis of global research production in respiratory medicine. Chest. 2005;128:3993–3998.
   PubMed Web of Science ®Google Scholar
• Vergidis PI, Karavasiou AI, Paraschakis K, et al. Bibliometric analysis of global trends for research productivity in microbiology. Eur J Clin Microbiol Infect Dis. 2005;24:342–346.
   PubMed Web of Science ®Google Scholar
• Liu YH, Wang SQ, Xue JH, et al. Hundred top-cited articles focusing on acute kidney injury: a bibliometric analysis. BMJ Open. 2016;6:e011630.
   PubMed Web of Science ®Google Scholar
• Shuaib W, Khan MS, Shahid H, et al. Bibliometric analysis of the top 100 cited cardiovascular articles. Am J Cardiol. 2015;115:972–981.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karavasiou AI, Bliziotis IA. A bibliometric analysis of global trends of research productivity in tropical medicine. Acta Trop. 2006;99:155–159.
   PubMed Web of Science ®Google Scholar
• Bornmann L. Do altmetrics point to the broader impact of research? An overview of benefits and disadvantages of altmetrics. J Informetr. 2014;8:895–903.
   Web of Science ®Google Scholar
• Aksnes DW, Langfeldt L, Wouters P. Citations, citation indicators, and research quality: an overview of basic concepts and theories. Sage Open. 2019;9:215824401982957.
   Web of Science ®Google Scholar
• Priem J, Taraborelli D, Groth P, et al. Altmetrics: a manifesto. Altmetrics; 2010 [accessed 2020 Jun 22]. Available from: http://altmetrics.org/manifesto
   Google Scholar
• Melero R. Altmetrics – a complement to conventional metrics. Biochem Med. 2015;25:152–160.
   Web of Science ®Google Scholar
• Powell AGMT, Bevan V, Brown C, et al. Altmetric versus bibliometric perspective regarding publication impact and force. World J Surg. 2018;42:2745–2756.
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence. Skin cancer. [accessed 2020 Apr 19]. Available from: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer/skin-cancer
   Google Scholar
• Joyce CW, Sugrue CM, Joyce KM, et al. 100 Citation classics in the melanoma literature: a bibliometric analysis. Dermatol Surg. 2014;40:1284–1298.
   PubMed Web of Science ®Google Scholar
• Paladugu R, Schein M, Gardezi S, et al. One hundred citation classics in general surgical journals. World J Surg. 2002;26:1099–1105.
   PubMed Web of Science ®Google Scholar
• Loonen MPJ, Hage JJ, Kon M. Plastic surgery classics: characteristics of 50 top-cited articles in four plastic surgery journals since 1946. Plast Reconstr Surg. 2008;121:320e–327e.
   PubMed Web of Science ®Google Scholar
• Powell AGMT, Hughes DL, Wheat JR, et al. The 100 most influential manuscripts in gastric cancer: a bibliometric analysis. Int J Surg. 2016;28:83–90.
   PubMed Web of Science ®Google Scholar
• Oxford Centre for Evidence Based Medicine. 2020 [accessed 2020 Apr 19]. Available from: https://www.cebm.net/2016/05/ocebm-levels-of-evidence/
   Google Scholar
• Eberlein TJ. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Yearb Surg. 2012;2012:353–356.
   Google Scholar
• Jukic DM. Distinct sets of genetic alterations in melanoma. Yearb Pathol Lab Med. 2007;2007:102–103.
   Google Scholar
• Kamb A. A cell cycle regulator potentially involved in genesis of many tumour types. Trends Genet. 1994;10:228.
   Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-{CTLA}-4 treatment ({CheckMate} 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117.
   PubMed Web of Science ®Google Scholar
• Thurner B, Haendle I, Röder C, et al. Vaccination with Mage-3a1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669–1678.
   PubMed Web of Science ®Google Scholar
• Brichard V, Pel A, Van Wölfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489–495.
   PubMed Web of Science ®Google Scholar
• Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739–752.
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647.
   PubMed Web of Science ®Google Scholar
• Dudley ME. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854.
   PubMed Web of Science ®Google Scholar
• Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human merkel cell carcinoma. Science. 2008;319:1096–1100.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129.
   PubMed Web of Science ®Google Scholar
• Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–1671.
   PubMed Web of Science ®Google Scholar
• Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363–1366.
   PubMed Web of Science ®Google Scholar
• Rubinfeld B. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997;275:1790–1792.
   PubMed Web of Science ®Google Scholar
• Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957–959.
   PubMed Web of Science ®Google Scholar
• Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959–961.
   PubMed Web of Science ®Google Scholar
• Allen EM, Van Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–211.
   PubMed Web of Science ®Google Scholar
• Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: {UV}-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci. 1991;88:10124–10128.
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci. 2003;100:8372–8377.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci. 1994;91:3515–3519.
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci. 2010;107:4275–4280.
   PubMed Web of Science ®Google Scholar
• Setlow RB. The wavelengths in sunlight effective in producing skin cancer: a theoretical analysis. Proc Natl Acad Sci. 1974;71:3363–3366.
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci. 2008;105:3041–3046.
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci. 2002;99:16168–16173.
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci. 1993;90:11307–11311.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Eng J Med . 2010;363:809–819.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–114.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Eng J Med . 2013;369:134–144.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Eng J Med . 1988;319:1676–1680.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with Vemurafenib. New Eng J Med . 2012;366:707–714.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. New Eng J Med . 2012;366:925–931.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. New Eng J Med . 1990;323:570–578.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. New Eng J Med . 2016;375:819–829.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New Eng J Med . 2014;371:1877–1888.
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–1290.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Rollin L, Larkin J. Nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:2503–2504.
   PubMed Web of Science ®Google Scholar
• Genetic basis for clinical response to CTLA-4 blockade. New Eng J Med . 2015;372:783.
   Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells. Nat Med. 1998;4:328–332.
   PubMed Web of Science ®Google Scholar
• Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med . 2012;18:883–891.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321–327.
   PubMed Web of Science ®Google Scholar
• Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med . 1999;5:677–685.
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet . 2002;33:19–20.
   PubMed Web of Science ®Google Scholar
• Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet . 1994;8:15–21.
   PubMed Web of Science ®Google Scholar
• DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996;14:457–460.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearly JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571.
   PubMed Web of Science ®Google Scholar
• Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542:115–118.
   PubMed Web of Science ®Google Scholar
• Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536–540.
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LCW, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720–724.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977.
   PubMed Web of Science ®Google Scholar
• Quintana E, Shackleton M, Sabel MS, Fullen DR, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–598.
   PubMed Web of Science ®Google Scholar
• Ziegler A, Jonason AS, Leffellt DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994;372:773–776.
   PubMed Web of Science ®Google Scholar
• Clark EA, Golub TR, Lander ES, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406:532–535.
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596–599.
   PubMed Web of Science ®Google Scholar
• Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–504.
   PubMed Web of Science ®Google Scholar
• Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–349.
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968–972.
   PubMed Web of Science ®Google Scholar
• Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117–122.
   PubMed Web of Science ®Google Scholar
• Xie J, Murone M, Luoh S-M, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391:90–92.
   PubMed Web of Science ®Google Scholar
• Victor CT-S, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–377.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF V600E. Nature. 2011;480:387–390.
   PubMed Web of Science ®Google Scholar
• Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63:8–18.
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206.
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635–3648.
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001;19:3622–3634.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–2357.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol . 2006;24:4340–4346.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol . 2008;26:5233–5239.
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–4557.
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–851.
   PubMed Web of Science ®Google Scholar
• Hodis E, Watson I, Kryukov G, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251–263.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–490.
   PubMed Web of Science ®Google Scholar
• Akbani R, Akdemir KC, Aksoy BA, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–1696.
   PubMed Web of Science ®Google Scholar
• Clark WH, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–727.
   PubMed Web of Science ®Google Scholar
• Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65:9328–9337.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683–695.
   PubMed Web of Science ®Google Scholar
• Allen AC, Spitz S. Malignant melanoma. A clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1–45.
   PubMed Web of Science ®Google Scholar
• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer. 1998;83:1664–1678.
   PubMed Web of Science ®Google Scholar
• Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250–281.
   PubMed Web of Science ®Google Scholar
• Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–908.
   PubMed Web of Science ®Google Scholar
• Clark WH, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893–1904.
   PubMed Web of Science ®Google Scholar
• Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011;378:1635–1642.
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol. 2016;17:184–192.
   PubMed Web of Science ®Google Scholar
• Amir M, Sampson BP, Endly D, et al. Social networking sites: emerging and essential tools for communication in dermatology. JAMA Dermatol. 2014;150:56.
   PubMed Web of Science ®Google Scholar
• Patel RR, Hill MK, Smith MK, et al. An updated assessment of social media usage by dermatology journals and organizations. Dermatol Online J. 2018;24:13030/qt3jr646v0.
   Google Scholar
• Global Digital Report 2019. We Are Social; 2019 [accessed 2020 Jul 5]. Available from: https://wearesocial.com/global-digital-report-2019
   Google Scholar
• Smart Insights. Global social media research summary 2020. Smart Insights; 2020.
   Google Scholar
• Marketing Land. The disastrous consequences of measuring engagement. 2018 [accessed 2020 Jul 5]. Available from: marketingland.com/the-disastrous-consequences-of-measuring-engagement-250863
   Google Scholar
• Björk BC, Solomon D. Open access versus subscription journals: a comparison of scientific impact. BMC Med. 2012;10:73.
   PubMed Web of Science ®Google Scholar